Your browser doesn't support javascript.
Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation.
Takahashi, Wakana; Yoneda, Taro; Koba, Hayato; Ueda, Tsukasa; Tsuji, Noriaki; Ogawa, Haruhiko; Asakura, Hidesaku.
  • Takahashi W; Department of Internal Medicine, Komatsu Municipal Hospital, Ho 60, Mukaimotoori-machi, Komatsu, Ishikawa 923-8560, Japan. Electronic address: wakanakita@gmail.com.
  • Yoneda T; Department of Internal Medicine, Komatsu Municipal Hospital, Ho 60, Mukaimotoori-machi, Komatsu, Ishikawa 923-8560, Japan. Electronic address: taroyoneda@yahoo.co.jp.
  • Koba H; Department of Internal Medicine, Komatsu Municipal Hospital, Ho 60, Mukaimotoori-machi, Komatsu, Ishikawa 923-8560, Japan. Electronic address: hayatokoba@gmail.com.
  • Ueda T; Department of Internal Medicine, Komatsu Municipal Hospital, Ho 60, Mukaimotoori-machi, Komatsu, Ishikawa 923-8560, Japan. Electronic address: blacktuna007@gmail.com.
  • Tsuji N; Department of Internal Medicine, Komatsu Municipal Hospital, Ho 60, Mukaimotoori-machi, Komatsu, Ishikawa 923-8560, Japan. Electronic address: noriakix1212m@gmail.com.
  • Ogawa H; Department of Environmental and Preventive Medicine, Kanazawa University, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8640, Japan. Electronic address: h-ogawa@jintikai.com.
  • Asakura H; Department of Hematology Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8640, Japan. Electronic address: hasakura@staff.kanazawa-u.ac.jp.
Int J Infect Dis ; 102: 529-531, 2021 Jan.
Article in English | MEDLINE | ID: covidwho-898988
ABSTRACT
Nafamostat, a serine proteinase inhibitor with various actions including antithrombin, antiplasmin, and antitrypsin effects, has been used in clinical practice to treat disseminated intravascular coagulation (DIC) and pancreatitis. This case report describes the clinical course of a patient with COVID-19 pneumonia whose severe hypoxemia, probably caused by DIC and pulmonary embolism, showed remarkable improvement with combination heparin and nafamostat therapy. In addition, beneficial mechanisms of nafamostat against COVID-19 and the necessity of attention to hyperkalemia as an adverse effect are discussed.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Disseminated Intravascular Coagulation / COVID-19 / Guanidines / Anticoagulants Type of study: Case report / Prognostic study Topics: Long Covid Limits: Aged / Humans / Male Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Disseminated Intravascular Coagulation / COVID-19 / Guanidines / Anticoagulants Type of study: Case report / Prognostic study Topics: Long Covid Limits: Aged / Humans / Male Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article